… study, no relationship was observed between the erlotinib plasma concentration and
pharmacodynamic … expression has promise as a surrogate marker of response to erlotinib. Phase …

… inhibition should be studied in tumor tissue. We conducted a pharmacodynamic study of
erlotinib, involving the prospective collection of tumor tissue samples from NSCLC patients. Our …

… studies of erlotinib (18) and panobinostat (13). The pharmacokinetic parameters for erlotinib
and panobinostat (14) seen in this study are … patients was comparable with prior studies that …

… Although the principal objective of the study was to assess the biological and pharmacodynamic
effects of erlotinib in serially sampled skin and tumor tissues obtained before and after …

… plasma erlotinib concentrations remains unclear.8, 9, 10 We carried out a study in which
forty-two patients … erlotinib. The aim of this pilot clinical trial was to assess the feasibility of using …

… Because erlotinib presents many similarities with imatinib (chemical structure, mechanism
… recommended for erlotinib is 150 mg for patients with NSCLC and 100 mg for patients with …

… (TKIs) in lung cancer.8, 11 These studies provide a strong rationale for combining a COX-2 …
The current phase I study investigated the combination of apricoxib plus erlotinib in patients …

… To the best of our knowledge, this study is the first to suggest that HNSCC patients … to
erlotinib therapy than patients with low EGFR gene copy number. Three recent reports, in patients …

… outcomes of erlotinib remains fully investigated. The primary objective of this study was to
clarify the population pharmacokinetics/pharmacodynamics of erlotinib in Japanese patients …

… Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal … The
aim of this study was to investigate the relationship between erlotinib plasma concentrations …